2031124-72-6
Chemical Structure
Meropenem-vaborbactam
Synonym(s): Carbavance
- CAS No.: 2031124-72-6
- Formula:C29H41BN4O10S2
- Molecular Weight:680.60
IUPAC Name: (4R,5S,6S)-3-(((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl)thio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid compound with 2-((3R,6S)-2-hydroxy-3-(2-(thiophen-2-yl)acetamido)-1,2-oxaborinan-6-yl)acetic acid (1:1)
InChIKey: SDJYWZHQLNEXKV-SSHSFQATSA-N
SMILES: OC(C1=C(S[C@H]2C[C@H](NC2)C(N(C)C)=O)[C@H](C)[C@@]([C@@]3([H])[C@H](O)C)([H])N1C3=O)=O.O=C(CC4=CC=CS4)N[C@@H]5B(O[C@@H](CC5)CC(O)=O)O
Biological Activity: Meropenem-vaborbactam (Carbavance) is a Carbapenem Antibiotic and Boronic acid-based beta-lactamase inhibitor, is a fixed-dose combination product with potent in vitro activity against Enterobacteriaceae that are Klebsiella pneumoniae carbapenemase producers. Meropenem-vaborbactam exhibits activity against Pseudomonas aeruginosa isolates , with an MIC50 of 0.5 μg/mL and an MIC90 of 8 μg/mL[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Meropenem-vaborbactam | 97.91% | Meropenem-vaborbactam (Carbavance) is a Carbapenem Antibiotic and Boronic acid-based beta-lactamase inhibitor, is a fixed-dose combination product with potent in vitro activity against Enterobacteriaceae that are Klebsiella pneumoniae carbapenemase producers. Meropenem-vaborbactam exhibits activity against Pseudomonas aeruginosa isolates , with an MIC50 of 0.5 μg/mL and an MIC90 of 8 μg/mL. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Castanheira M, et al. Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2017;61(9):e00567-17. Published 2017 Aug 24. [Content Brief]
- [2]. Petty LA, et al. Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae. Infect Drug Resist. 2018 Sep 12;11:1461-1472. [Content Brief]
Keywords
